The aim of this article is to describe potential alternatives to @entity1 no longer eligible for management with @entity176 for @entity170 according to the recommendations by the European Medicines Agency. A systematic search of Pubmed was done for papers on @entity174 efficacy of various treatments for @entity170 , and potential harms especially in terms of cardiovascular events and @entity64 . The results showed that drugs more efficacious in terms of relative risk reduction of @entity174 than @entity176 were @entity561 , @entity562 , @entity4381 , and denosumab. @entity441 , as for @entity9756 , may be associated with an increased risk of @entity1211 and fatal @entity64 . In terms of cardiovascular events special attention may be given to @entity460 supplements. Thus, @entity1 at risk of @entity64 and ischemic @entity299 such as @entity583 should not use @entity176 . Ideally more efficacious drugs in terms of @entity174 reduction should be used such as @entity561 , @entity562 , @entity4381 or denosumab. @entity441 may pose a special problem as this too may be associated with an increased risk of @entity64 . Other less-potent drugs in terms of @entity174 reduction should only be used if no alternatives are available ( @entity7923 , @entity5279 , @entity19160 ). @entity461 or analogs may be used for a limited time interval in specially selected @entity1 and needs to be followed up with antiresorptive treatment to prevent @entity604 . However, it should be remembered that no head-to-head comparison studies exist.

New strategies for @entity170 XXXX previously managed with @entity176 .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity64 :: ('MESH:D020521', 'Disease') :: ['fatal strokes', 'stroke'] @entity583 :: ('MESH:D009203', 'Disease') :: ['acute myocardial infarction'] @entity174 :: ('MESH:D050723', 'Disease') :: ['fractures', 'fracture'] @entity5279 :: ('MESH:C019248', 'Chemical') :: ['pamidronate'] @entity561 :: ('MESH:D019386', 'Chemical') :: ['alendronate'] @entity170 :: ('MESH:D010024', 'Disease') :: ['osteoporosis'] @entity604 :: ('MESH:D016301', 'Disease') :: ['loss of the bone gained'] @entity7923 :: ('MESH:C073007', 'Chemical') :: ['ibandronate'] @entity562 :: ('MESH:C073008', 'Chemical') :: ['risedronate'] @entity9756 :: ('MESH:D013324', 'Chemical') :: ['strontium'] @entity19160 :: ('MESH:D004002', 'Chemical') :: ['clodronate'] @entity460 :: ('MESH:D002118', 'Chemical') :: ['calcium'] @entity299 :: ('MESH:D006331', 'Disease') :: ['cardiac events'] @entity4381 :: ('MESH:C088658', 'Chemical') :: ['zoledronate'] @entity176 :: ('MESH:C081587', 'Chemical') :: ['strontium ranelate'] @entity1211 :: ('MESH:D054556', 'Disease') :: ['deep venous thromboembolism'] @entity461 :: ('5741', 'Gene') :: ['Parathyroid hormone'] @entity441 :: ('MESH:D020849', 'Chemical') :: ['Raloxifene']
@entity1 :: (9606,Species) :: ['patients']
